BLA 761411 · Incyte Corp
Niktimvo
Axatilimab-Csfr · Intravenous · Colony Stimulating Factor-1 Receptor Blocker
NovelPriority reviewOrphanCDER novel approval, Aug 14, 2024: To treat chronic graft-versus-host disease (cGVHD)
Last checked: Nov 20, 2026Latest source record: Aug 14, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Aug 14, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
27
3 Phase 3, 11 recruiting
FAERS reports
163
56 serious, 14 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 25, 2026.
NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. NIKTIMVO is a colony stimulating factor-1 receptor (CSF-1R)-blocking antibody indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. ( 1 )
Mechanism: Axatilimab-csfr is a monoclonal antibody that binds to colony stimulating factor-1 receptors (CSF-1R) expressed on monocytes and macrophages. Blocking CSF-1R with axatilimab-csfr reduces the levels of these circulating proinflammatory and profibrotic monocytes and monocyte-derived macrophages, as demonstrated by a reduction of nonclassical monocyte counts in nonclinical studies with axatilimab-csfr, and inhibits the activity of pathogenic macrophages in tissues.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 14, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- NIKTIMVO · axatilimab-csfr 50 MG/ML · INJECTABLE, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Axatilimab" as an intervention, any sponsor and status, largest first.
- A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)Pivotal-lookingRecruiting
Syndax PharmaceuticalsIndustry
NCT04710576 · 296 participants (planned) · Start Mar 4, 2021 · Primary completion Apr 7, 2023
Drug: Axatilimab · For: Chronic Graft-versus-host-disease
Sites: Birmingham, Alabama; Duarte, California; Los Angeles, California · 121 sites in all
- A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseasePivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT06585774 · 240 participants (planned) · Start Jan 21, 2025 · Primary completion Sep 28, 2027
Drug: INCA034176; Placebo and 1 more · For: Chronic Graft-versus-host-disease
Sites: Birmingham, Alabama; Tucson, Arizona; Duarte, California · 133 sites in all
- MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingCompleted
Syndax PharmaceuticalsIndustry
NCT06132256 · 145 participants · Start Dec 11, 2023 · Primary completion Aug 27, 2026
Drug: Axatilimab · For: Idiopathic Pulmonary Fibrosis
Sites: Camperdown, Australia; Birtinya, Australia; Brisbane, Australia · 78 sites in all
- A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseasePivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT06388564 · 130 participants · Start Oct 11, 2024 · Primary completion Oct 1, 2026
Drug: Axatilimab; Ruxolitinib and 1 more · For: Chronic Graft-versus-host-disease
Sites: Phoenix, Arizona; Duarte, California; Los Angeles, California · 68 sites in all
Incyte CorporationIncyte (INCY)
NCT06713590 · 72 participants · Start Jan 14, 2025 · Primary completion Jun 6, 2025
Drug: Axatilimab · For: Healthy Participants
Sites: Tempe, Arizona
- CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell TransplantationNot yet recruiting
Medical College of WisconsinAcademic, hospital or other
NCT07808112 · 72 participants (planned) · Start Nov 2026 · Primary completion Nov 2031
Drug: Cyclophosphamide; Tacrolimus and 2 more · For: Graft -Versus-host-disease
Sites: Milwaukee, Wisconsin
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07128381 · 66 participants (planned) · Start Jan 2, 2026 · Primary completion Jul 31, 2031
Drug: Axatilimab (SNDX-6352); Ruxolitinib · For: Myelofibrosis (MF); Chronic Myelomonocytic Leukemia (CMML)
Sites: Houston, Texas
Incyte CorporationIncyte (INCY)
NCT07124078 · 60 participants (planned) · Start May 20, 2026 · Primary completion Jan 31, 2029
Drug: INCA034176; Best available Treatment (BAT) · For: Chronic Graft-versus-host-disease
Sites: Duarte, California; Los Angeles, California; Palo Alto, California · 42 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use38
- product dose omission issue8
- infusion related reaction7
- liver function test increased7
- death6
- dyspnoea6
- fatigue6
- inappropriate schedule of product administration6
- nausea6
- condition aggravated5
- diarrhoea5
- anaphylactic reaction4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 82 |
| 2026 | 78 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.
Wolff D, Cutler C, Lee SJ, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Multicenter Study
- Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.
Kitko CL, Arora M, DeFilipp Z, et al. · J Clin Oncol 2023 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Efficacy and safety of axatilimab in chronic graft-versus-host disease: A systematic review and meta-analysis.
Bahbah EI, Attia M, Ali M · Crit Rev Oncol Hematol 2025 · Systematic Review, Meta-Analysis
- Exposure-Response Relationships for Axatilimab in Patients with Chronic Graft-Versus-Host Disease.
Yang YO, Volkova A, Sokolov V, et al. · Clin Pharmacol Ther 2025 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study.
Haranaka M, Kinami K, Yang YO, et al. · Clin Drug Investig 2025 · Randomized Controlled Trial, Clinical Trial, Phase I
- Optimal Treatment of Steroid-refractory Chronic Graft-versus-host Disease (cGvHD) in the Era of Novel drugs - a Systematic Review and Meta-analysis.
Karaszewski K, Sekua M, Jwdrzejczak WW · Stem Cell Rev Rep 2026 · Systematic Review, Meta-Analysis
Sponsor: Incyte
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.